Trial reportAesthetic plastic surgery2026
Efficacy and Safety of LetibotulinumtoxinA Injection for Trapezius Hypertrophy: A Prospective, Randomized, Double-Blind Trial.
Trial report in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrapezius hypertrophy is a significant aesthetic concern among women. Botulinum toxin has emerged as a potential treatment option for this condition. In this study, we conducted a prospective, randomized, double-blind trial to evaluate the effectiveness and safety of letibotulinumtoxinA specifically for women.
methodsWe conducted a prospective study between July 2022 and June 2023, recruiting 20 patients seeking treatment for trapezius hypertrophy. LetibotulinumtoxinA (Botulax®) was used as the neurotoxin. The patients were randomized into group A (n = 10, 40 units) and group B (n = 10, 80 units). Each group received different doses of toxin at 10 injection points along the trapezius muscle.
resultsWe analyzed the contour changes in two groups and calculated the average area before and after treatment. After 12 weeks post-treatment, both groups demonstrated a decrease in the trapezius area with statistically significant differences (p = 0.011, p = 0.005). The median satisfactory score was 4, indicating a moderate level of satisfaction in both groups. No statistically significant differences or complications were observed between the groups.
conclusionLetibotulinumtoxinA for trapezius hypertrophy demonstrated efficacy with no differences between two experimental groups. Aesthetic concerns were addressed, enhancing shoulder and neck appearance with a high degree of satisfaction. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
41927997What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.